OverviewSuggest Edit

Sorrento Therapeutics is a biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs. Sorrento's primary therapeutic focus is cancer although its products and technologies have much broader clinical applications including autoimmune disorders, metabolic diseases and infectious diseases. The Company's lead programs consist of four Phase III BioSimilar/BioBetter antibodies. It is also advancing a portfolio of adoptive cellular therapies, immuno-oncology mAbs, and antibody drug conjugates (ADCs).
TypePublic
Founded2006
HQSan Diego, CA, US
Websitesorrentotherapeutics.com
Employee Ratings3.4
Overall CultureD

Latest Updates

Employees (est.) (Dec 2019)310(-18%)
Job Openings69
Revenue (FY, 2020)$40 M(+28%)
Share Price (Sept 2021)$8.1(+2%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Sorrento Therapeutics

Henry Ji

Henry Ji

Chairman, President and CEO
Mike Royal

Mike Royal

Chief Medical Officer
Edgar Lee

Edgar Lee

Director
David Lemus

David Lemus

Director
Najjam Asghar

Najjam Asghar

SVP - Chief Financial Officer
Mark R. Brunswick

Mark R. Brunswick

SVP - Regulatory Affairs
Show more

Sorrento Therapeutics Office Locations

Sorrento Therapeutics has an office in San Diego
San Diego, CA, US (HQ)
4955 Directors Pl
San Diego, CA, US
9380 Judicial Dr
Show all (2)

Sorrento Therapeutics Financials and Metrics

Sorrento Therapeutics Revenue

Sorrento Therapeutics's revenue was reported to be $39.99 m in FY, 2020
USD

Revenue (Q1, 2021)

14.3m

Net income (Q1, 2021)

2.4m

EBIT (Q1, 2021)

(84.9m)

Market capitalization (23-Sept-2021)

2.4b

Closing stock price (23-Sept-2021)

8.1

Cash (31-Mar-2021)

41.7m

EV

2.5b
Sorrento Therapeutics's current market capitalization is $2.4 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

529.2k583.8k460.1k3.8m4.6m8.2m151.9m21.2m31.4m40.0m

Revenue growth, %

731%20%78%

Cost of goods sold

4.4k2.0m2.0m811.0k3.9m7.1m

Gross profit

455.7k1.8m2.6m7.3m147.9m14.1m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q1, 2020Q2, 2020Q1, 2021

Revenue

74.2k91.8k110.1k217.1k134.5k134.1k83.8k976.0k775.0k1.3m977.0k1.2m1.1m988.0k902.0k2.2m4.9m4.7m121.9m6.2m3.9m4.1m6.1m7.7m9.0m14.3m

Cost of goods sold

563.0k510.0k527.0k509.0k314.0k604.0k359.0k295.0k418.0k1.1m816.0k1.1m1.3m1.2m2.2m2.3m

Gross profit

413.0k265.0k749.0k468.0k859.0k499.0k629.0k607.0k1.8m3.8m3.8m120.8m4.9m2.7m1.9m3.8m

Gross profit Margin, %

42%34%59%48%73%45%64%67%81%78%83%99%79%69%47%62%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2020

Cash

3.5m5.1m31.7m71.9m39.0m82.4m20.4m158.7m56.5m

Accounts Receivable

2.2m3.8m15.5m

Prepaid Expenses

29.9k80.9k4.9m6.6m8.7m

Inventories

1.8m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

2.9m2.3m2.4m7.6m6.4m9.6m5.8m6.4m29.9m50.2m44.3m60.5m51.7m59.1m20.8m98.2m66.5m33.9m53.7m38.3m24.3m46.8m135.4m91.0m21.9m24.4m41.7m

Accounts Receivable

657.0k576.0k986.0k784.0k898.0k622.0k1.1m867.0k526.0k2.3m2.4m1.7m3.9m7.4m10.0m13.8m16.3m

Prepaid Expenses

4.8k41.3k22.6k13.6k66.8k688.7k75.0k407.6k626.0k705.0k586.0k879.0k1.2m731.0k1.9m556.0k1.1m3.3m2.4m2.3m6.2m5.5m14.7m14.4m7.7m

Inventories

4.6m3.0m2.4m1.8m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(3.2m)(4.8m)(21.9m)(34.7m)(50.1m)(63.9m)11.1m(212.5m)(363.0m)(314.4m)

Depreciation and Amortization

159.2k293.3k1.3m3.2m2.4m2.9m7.1m9.1m11.0m11.0m

Inventories

(3.2m)

Accounts Payable

42.9k(23.2k)878.6k(497.0k)(2.7m)3.7m1.6m3.6m10.2m(3.7m)
USDQ2, 2011

Financial Leverage

1.1 x
Show all financial metrics

Sorrento Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

SecurityScorecard logo

Sorrento Therapeutics Online and Social Media Presence

Embed Graph

Sorrento Therapeutics Company Culture

  • Overall Culture

    D

    58/100

  • CEO Rating

    F

    53/100

  • Compensation

    D

    55/100

Learn more on Comparably

Sorrento Therapeutics News and Updates

Sorrento Therapeutics Announces Entry Into Option Agreement to Exclusively License MPRO Inhibitors Against SARS-CoV-2 and Variants of Concern, Including Delta, From Texas A&M University

SAN DIEGO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that it has entered into an option agreement (“Option”) with The Texas A&M University System (“TAMUS”) for exclusive rights to the intellectual property covering highly potent ma…

Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary Announces Expansion of Ztlido® Managed Care Coverage for Additional 33 Million Lives

PALO ALTO, Calif., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Scilex Holding Company (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE), announced that, effective September 1, 2021, ZTlido® (lidocaine topical system) 1.8% has been added to multiple formularies, including two national PBMs…

Aardvark Therapeutics, Inc., Completes $29m Series B Funding Led By Sorrento Therapeutics And Including Existing Investors And The Foundation For Prader-Willi Research

SAN DIEGO, Aug. 5, 2021 /PRNewswire/ -- Aardvark Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing and commercializing novel small molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, inflammation, and...

Is A Fall In Sorrento Therapeutics Stock Imminent After A 28% Rise In A Month?

Earlier this month we discussed that the stock of Sorrento Therapeutics (NASDAQ: SRNE) is best avoided given the large rally it has seen in a short time period. While SRNE stock declined over 8% from levels of $9.46 on June 14 to $8.69 on June 21, it has since rallied 14% to $9.90 now...

What’s Next For Sorrento Therapeutics Stock After A Large 50% Rise In A Month?

The stock price of Sorrento Therapeutics (NASDAQ: SRNE), a clinical stage biopharma company that develops treatments for cancer and neurodegenerative diseases among others, has seen a solid 49% rise over the last twenty-one trading sessions, led by multiple positive developments...

Thinking about buying stock in Mereo BioPharma, Lipocine, Lordstown Motors, Sorrento Therapeutics, or Axcella Health?

NEW YORK, June 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MREO, LPCN, RIDE, SRNE, and AXLA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
Show more

Sorrento Therapeutics Blogs

Sorrento Announces That COVISTIX™ (COVID-19 Virus Rapid Antigen Detection Test) Has Received a CE Mark and Registration of the Device

Sorrento Announces That COVISTIX™ (COVID-19 Virus Rapid Antigen Detection Test) Has Received a CE Mark and Registration of the Device Content Import Wed, 10/20/2021 - 13:37 Sorrento Announces That COVISTIX™ (COVID-19 Virus Rapid Antigen Detection Test) Has Received a CE Mark and Registrati…

CORRECTION - Sorrento Therapeutics, Inc.

SAN DIEGO , Sept. 28, 2021 (GLOBE NEWSWIRE) -- In a release issued on Tuesday, September 28th by  Sorrento Therapeutics, Inc. (NASDAQ: SRNE), please note that the date of the conference has been corrected to " September 29th " in the headline. The corrected release follows: Sorrento to Participate

Dr. Henry Ji, Sorrento Chairman and CEO, to Participate in the Virtual Cantor Global Healthcare Conference on September 29th, 2021

Dr. Henry Ji, Sorrento Chairman and CEO, to Participate in the Virtual Cantor Global Healthcare Conference on September 29th, 2021 Content Import Mon, 09/27/2021 - 13:13 Dr. Henry Ji, Sorrento Chairman and CEO, to Participate in the Virtual Cantor Global Healthcare Conference on September …

Sorrento Announces Enrollment of First Subject in Brazil Phase 2 Study of COVI-MSC for Treatment of COVID-19 Associated Acute Respiratory Distress in ICU Patients

Sorrento Announces Enrollment of First Subject in Brazil Phase 2 Study of COVI-MSC for Treatment of COVID-19 Associated Acute Respiratory Distress in ICU Patients Content Import Thu, 09/02/2021 - 11:35 Sorrento Announces Enrollment of First Subject in Brazil Phase 2 Study of COVI-MSC for T…

Sorrento Exercises Exclusive Option Agreement With Texas A&M University for MPRO Inhibitors Against Sars-Cov-2 and all Variants of Concern

Exclusive license for M P ro inhibitors supports rapidly growing small molecule development portfolio for combating COVID-19. Lead compound, MPI8, exhibited potent in vitro antiviral activity against SARS-CoV-2 and all of the major Variants of Concern (VoCs) (alpha, beta, delta and gamma).

Sorrento Reports Promising Results With mRNA Vaccine For COVID-19 Delivered With The MuVaxx Lymphatic Drug Delivery Device

Sorrento’s mRNA vaccine (“STI-mRNA”) delivered with the MuVaxx™ Lymphatic Drug Delivery Device (“MuVaxx”), at 1/10th of the dose vs an LNP-mRNA reference standard 1 (“LNP-mRNA”) delivered intramuscularly (“IM”), demonstrated in preclinical studies a 400% improvement in cellular immunity and similar
Show more

Sorrento Therapeutics Frequently Asked Questions

  • When was Sorrento Therapeutics founded?

    Sorrento Therapeutics was founded in 2006.

  • Who are Sorrento Therapeutics key executives?

    Sorrento Therapeutics's key executives are Henry Ji, Mike Royal and Edgar Lee.

  • How many employees does Sorrento Therapeutics have?

    Sorrento Therapeutics has 310 employees.

  • What is Sorrento Therapeutics revenue?

    Latest Sorrento Therapeutics annual revenue is $40 m.

  • What is Sorrento Therapeutics revenue per employee?

    Latest Sorrento Therapeutics revenue per employee is $129 k.

  • Who are Sorrento Therapeutics competitors?

    Competitors of Sorrento Therapeutics include Celyad, Alnylam Pharmaceuticals and Luna Innovations.

  • Where is Sorrento Therapeutics headquarters?

    Sorrento Therapeutics headquarters is located at 4955 Directors Pl, San Diego.

  • Where are Sorrento Therapeutics offices?

    Sorrento Therapeutics has an office in San Diego.

  • How many offices does Sorrento Therapeutics have?

    Sorrento Therapeutics has 2 offices.